First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas—a single-centre experience in 61 patients

被引:0
作者
T. Brezina
H. von Dewitz
T. Schroeder
S. Ullrich
K. Nachtkamp
G. Reifenberger
B. Malzkorn
M. Sabel
R. Haas
G. Kobbe
机构
[1] University Hospital Zuerich,Department of Oncology
[2] Hospital Merheim,Department of Internal Medicine A
[3] University Hospital Duesseldorf,Department of Haematology, Medical Faculty
[4] Heinrich Heine University Duesseldorf,Department of Neuropathology
[5] Life Science Center for Statistics,Department of Neurosurgery
[6] University Hospital Duesseldorf,undefined
[7] University Hospital Duesseldorf,undefined
来源
Annals of Hematology | 2022年 / 101卷
关键词
Primary CNS lymphoma; High-dose chemotherapy; Hematopoietic stem cell transplantation; Methotrexate;
D O I
暂无
中图分类号
学科分类号
摘要
Primary central nervous system non-Hodgkin lymphomas (PCNS-NHLs) are extranodal B-cell lymphomas with poor prognosis. The role of high-dose therapy (HDT) followed by autologous blood stem cell transplantation (ASCT) as first-line therapy is still not clear. We retrospectively collected long-term follow up data of 61 consecutive patients with PCNS-NHL at the University Hospital Düsseldorf from January 2004 to December 2016. Thirty-six patients were treated with conventional chemoimmunotherapy (cCIT) only (CT-group). Seventeen patients received an induction cCIT followed by HDT and ASCT. In the CT-group, the overall response rate (ORR) was 61% (CR 47%, PR 14%), and there were 8% treatment-related deaths (TRD). Progression-free survival (PFS) was 31.8 months, and overall survival (OS) was 57.3 months. In the HDT-group, the ORR was 88% (59% CR, 29% PR), and there were 6% TRD. Median PFS and OS were not reached at 5 years. The 5-year PFS and OS were 64.7%. After a median follow up of 71 months, 10 patients (59%) were still alive in CR/PR following HDT and ASCT, one patient was treated for progressive disease (PD), and 7 had died (41%, 6 PD, 1 TRD). All patients achieving CR prior to HDT achieved durable CR. In the CT-group, 8 patients (22%) were alive in CR/PR after a median follow-up of 100 months. Twenty-eight patients died (78%, 24 PD, 2 TRD, 2 deaths in remission). In the univariate analysis, the HDT-group patients had significantly better PFS (not reached vs 31.8 months, p = 0.004) and OS (not reached vs 57.3 months, p = 0.021). The multivariate analysis showed HDT was not predictive for survival. Treatment with HDT + ASCT is feasible and offers the chance for long-term survival with low treatment-related mortality in younger patients. In this analysis, ORR, PFS and OS were better with HDT than with conventional cCIT alone. This result was not confirmed in the multivariate analysis, and further studies need to be done to examine the role of HDT in PCNSL.
引用
收藏
页码:607 / 616
页数:9
相关论文
共 219 条
[1]  
Giannini C(2014)CNS lymphoma: a practical diagnostic approach J Neuropathol Exp Neurol 73 478-494
[2]  
Dogan A(1992)Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315 Int J Radiat Oncol Biol Phys 23 9-17
[3]  
Salomão DR(2005)Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s Int J Radiat Oncol Biol Phys 62 809-813
[4]  
Nelson DF(2015)The role of radiation therapy in the management of primary central nervous system lymphoma Leuk Lymphoma 56 1197-1204
[5]  
Martz KL(2010)High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial Lancet Oncol 11 1036-1047
[6]  
Bonner H(2003)Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96–07 J Clin Oncol 21 1044-1049
[7]  
Nelson JS(2008)Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation Neurology 70 401-402
[8]  
Newall J(2009)High-dose methotrexate for elderly patients with primary CNS lymphoma Neuro Oncol 11 211-215
[9]  
Kerman HD(2000)Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma J Clin Oncol 18 519-526
[10]  
Thomson JW(2002)A multicenter study of treatment of primary CNS lymphoma Neurology 58 1513-1520